A randomized double-blind placebo-controlled 2-arm Phase III study to assess efficacy and safety of xevinapant and radiotherapy compared to placebo and radiotherapy for demonstrating improvement of disease-free survival in participants with resected sq

Brief description of study

This is a study for patients diagnosed with squamous cell carcinoma of the head and neck who are at a high risk of the cancer coming back and unable to receive high-dose cisplatin. The study will have two groups, and patients will be randomly placed into one of the groups. One group will receive xevinapant and radiotherapy, and the other group will receive a placebo and radiotherapy. The study is double-blind, which means that neither the patients nor the doctors will know who is receiving xevinapant and who is receiving the placebo. The purpose of the study is to find out if xevinapant, when given with radiotherapy, can help patients live longer without their cancer coming back compared to radiotherapy alone.

Clinical Study Identifier: s22-01241

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.